


**AMENDMENTS TO THE CLAIMS**


1. (original) A method of treating or preventing an amyloid-related disease in a subject comprising administering to a subject a therapeutically effective amount of a compound, wherein said compound is selected from the group consisting of  
*N*-(6-aminoheptyl)-4-bromobenzamidine (compound #145),  
4-bromo-*N*-{7-[(4-bromobenzimidoyl)-amino]-heptyl}-benzamide (compound #146),  
*N*-hydroxy-4-(9-hydroxyaminononyloxy)-benzamidine (compound #147),  
*N*-[7-(4-carbamimidoylbenzoylamino)-heptyl]-terephthalamic acid ethyl ester (compound #148),  
*N*-[9-(4-carbamimidoyl-benzoylamino)-nonyl]-terephthalamic acid ethyl ester (compound #149),  
4,4'-(pentamethylenediamidino)di(*p*-bromobenzene) (compound #150),  
4,4'-(nonamethylenediamidino)di(*p*-bromobenzene) (compound #151),  
4,4'-(nonamethylenediamidino)di(*p*-methoxybenzene) (compound #152),  
4-methoxy-*N*-{2-[2-(4-methoxyphenyl)-4,5-dihydroimidazol-1-yl]-ethyl}-benzamidine (compound #153),  
4,4'-(pentamethylenediamidino)di(*p*-methoxybenzene) (compound #154),  
2,2'-(*p*-amidinophenylcarboxamido)-*N,N*-diethyl-*p*-amidinobenzamide (compound #155),  
{4-[5-(*p*-aminophenoxy)-pentyloxy]-phenyl}-(4,5-dihydro-1*H*-imidazol-2-yl)-amine (compound #156),  
4,4'-(nonamethylenedisulfamyl)di(amidinobenzene) (compound #158),  
3,3'-(pentamethylenediaminocarbonyl)di(amidinobenzene) (compound #159),  
4,4'-(tetramethylenediaminocarbonyl)di(amidinobenzene) (compound #160), and  
pharmaceutically acceptable salts thereof.
2. (original) The method according to claim 1, wherein said subject is in need of treating or preventing of said amyloid-related disease.
3. (currently amended) The method according to **claim 2** ~~any one of claims 1-2~~, wherein said amyloid-related disease is associated with IAPP.
4. (currently amended) The method according to **claim 2** ~~any one of claims 1-2~~, wherein said amyloid-related disease is associated with  $\beta$ -amyloid.

5. (currently amended) The method according to **claim 2** ~~any one of claims 1-2~~, wherein said amyloid-related disease is, Alzheimer's disease, Down's syndrome, type II diabetes, Mild Cognitive Impairment, age-related macular degeneration, or cerebral amyloid angiopathy.
6. (currently amended) The method according to **claim 2** ~~any one of claims 1-2~~, wherein said compound is adapted to be administered orally.
7. (original) The method according to claim 2, where said subject is a human.
8. (currently amended) A chemical compound **selected from the group consisting of** ~~having the following structure:~~




~~and pharmaceutically acceptable salts thereof.~~

- ~~9. A chemical compound having the following structure:~~




~~and pharmaceutically acceptable salts thereof.~~

- ~~10. A chemical compound having the following structure:~~




~~and pharmaceutically acceptable salts thereof.~~

~~11. A chemical compound having the following structure:~~




~~and pharmaceutically acceptable salts thereof.~~

~~12. A chemical compound having the following structure:~~




~~and pharmaceutically acceptable salts thereof.~~

~~13. A chemical compound having the following structure:~~




~~and pharmaceutically acceptable salts thereof.~~

~~14. A chemical compound having the following structure:~~




~~and pharmaceutically acceptable salts thereof.~~

~~15. A chemical compound having the following structure:~~




~~and pharmaceutically acceptable salts thereof.~~

~~16. A chemical compound having the following structure:~~




~~and pharmaceutically acceptable salts thereof.~~

~~17. A chemical compound having the following structure:~~




~~and pharmaceutically acceptable salts thereof.~~

~~18. A chemical compound having the following structure:~~




~~and pharmaceutically acceptable salts thereof.~~

~~19. A chemical compound having the following structure:~~




~~and pharmaceutically acceptable salts thereof.~~

~~20. A chemical compound having the following structure:~~




~~and pharmaceutically acceptable salts thereof.~~

~~21. A chemical compound having the following structure:~~



~~and pharmaceutically acceptable salts thereof.~~

~~22. A chemical compound having the following structure:~~



and pharmaceutically acceptable salts thereof.

9-22. (cancelled)

23. (currently amended) A pharmaceutical composition comprising a compound according to **claim 8** ~~any one of claims 8-22~~.

24. (original) The composition according to claim 23, further comprising a pharmaceutically acceptable vehicle.

25. (currently amended) A pharmaceutical composition for the treatment or prevention of an amyloid-related disease comprising a therapeutically effective amount of a compound according to **claim 8** ~~any one of claims 8-22~~.

26. (original) The composition according to claim 25, wherein said amyloid-related disease is Alzheimer's disease, Down's syndrome, type II diabetes, Mild Cognitive Impairment, age-related macular degeneration, or cerebral amyloid angiopathy.